trending Market Intelligence /marketintelligence/en/news-insights/trending/izfb4xwpjmkofq4w19z4iw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Roche hemophilia drug sees positive phase 3 study results

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Roche hemophilia drug sees positive phase 3 study results

Roche Holding Ltd.'s hemophilia A drug candidate met its primary- and- secondary endpoints in a phase 3 study.

ACE910, or emicizumab, showed a significant reduction in the number of bleeds over time in 12-year-old patients and older when compared to no prophylactic treatment.

The company also said it had resolved the thrombosis concerns raised earlier during the trial.